Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six
00

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Nov 16, 2026

Full trial results released on November 16, 2026 demonstrate that Novo Nordisk's Wegovy significantly reduces body mass index in children aged 6 to under 12, with 40 percent no longer classified as obese after 68 weeks. The findings address a growing global health burden affecting 177 million young people. However, research highlights concerns as younger children taking weight-loss drugs grew more slowly on average. Novo Nordisk has not yet set a timeline for filing regulatory approval for under-12s.

Wegovy pediatric trial results

  • ▪Filip Knop of Novo Nordisk stated that Wegovy improved blood sugar control and cardiovascular health in children aged 6 to under 12 during the 68-week trial
  • ▪Novo Nordisk's Wegovy trial followed 165 to 167 children aged 6 to under 12, more than 85 percent of whom had severe obesity at baseline
  • ▪Full trial results showed Novo Nordisk's Wegovy helped children aged 6 to under 12 with obesity shed weight and lower their body mass index
  • ▪In Novo Nordisk's trial, Wegovy lowered body mass index by an estimated average of 19.7 percentage points compared to placebo at 68 weeks for children aged 6 to under 12 who remained on treatment
  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group

Childhood obesity disease burden

  • ▪Childhood obesity global prevalence quadrupled from 2 percent in 1990 to 8 percent of 5- to 19-year-olds in 2024, according to the World Health Organization
  • ▪Unicef reported that more school-aged children and adolescents are estimated to be obese than underweight, with 81 percent of overweight 5- to 19-year-olds living in low- and middle-income countries

Growth slowdown safety signal

  • ▪Novo Nordisk reported observing no safety concerns regarding physical growth or pubertal development during its trial of Wegovy in children aged 6 to under 12
  • ▪Research presented this week indicated that elementary-school-age children taking weight-loss drugs grew more slowly on average than those who did not
  • ▪Novo Nordisk's Wegovy trial in children aged 6 to under 12 showed side effects similar to adults, including nausea, diarrhoea, and vomiting

Wegovy approval age gap

  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy
  • ▪Wegovy is approved to treat obesity in adolescents aged 12 and older in the United States, United Kingdom, and European Union, but has no approved indications for children under 12

Zepbound adolescent trial results

  • ▪Trial results reported at the weekend showed Eli Lilly's Zepbound reduced body mass index in adolescents aged 12 to under 18 by an average of 21.4 percent over 72 weeks
  • ▪Eli Lilly's Zepbound helped lower blood sugar and certain cholesterol levels in trial participants aged 12 to under 18

3 sources

CNBC
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
View source article
The Wall Street Journal
Weight-Loss Drugs for Elementary-Age Children Succeed in Study
View source article
Financial Times
Six-year-olds. Novo’s new frontier for weight-loss drugs
View source article

Story comments

Loading comments…

Related entities

World Health OrganizationUnited KingdomUnited StatesWegovy

Related Projects

UNICEFEuropean Union

Topics

Clinical trialsDrug Policy, Pricing & ApprovalObesity treatmentNovo NordiskDrug safetyAdolescent healthGLP-1 drugsZepboundChildhood obesityWeight loss drugsEli Lilly